Abstract

CRUSH - Antiviral Drug Screening and Resistance Hub is a fully integrated translational hub within MRC-University of Glasgow Centre for Virus Research (CVR) dedicated to accelerating antiviral therapeutic discoveries. CRUSH capabilities span both in vitro and in vivo studies, including primary drug screens, secondary screens in primary cells, drug combination studies, drug resistance assays, serological and molecular assays, and pre-clinical studies in experimental animal models. 

CRUSH was originally developed to respond to the SARS-CoV-2 pandemic but since then the facility has already adopted new viral systems (Mpox, Influenza A virus, rotaviruses). The long-term goal of CRUSH is to create a stable and sustainable resource for the UK’s academic and industrial community to help accelerate drug discovery for any known or novel high consequence virus requiring high containment facilities.